How Will Anteris’ $320M Raise Accelerate Its Heart Valve Breakthrough?

• Raised approximately US$320 million through public offering and Medtronic private placement
• 40 million shares sold publicly at US$5.75 each, including full underwriter option exercise
• Medtronic acquired 15.65 million shares in a private placement at the same price
• Funds earmarked for DurAVR pivotal trial, manufacturing expansion, and R&D